accelerating commercial development and partnership-seeking activities for Imeglimine outside Japan, PXL 770 and PXL 065, significantly reducing the Company's costs, and clearing the Company's ...
A capital increase with preferential subscription rights, allowing shareholders to subscribe at a highly attractive discount. Shareholders not participating may sell their subscription rights on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results